Anticancer activity of 7,8-dihydroxyflavone in melanoma cells via downregulation of α-MSH/cAMP/MITF pathway

Sim,Deok  Yong; Sohng,Jae  Kyung; Jung,Hye  Jin

doi:10.3892/or.2016.4825

Anticancer activity of 7,8-dihydroxyflavone in melanoma cells via downregulation of α-MSH/cAMP/MITF pathway

Authors:
- Deok Yong Sim
- Jae Kyung Sohng
- Hye Jin Jung
View Affiliations

Affiliations: Department of BT-Convergent Pharmaceutical Engineering, Sun Moon University, Chungnam 336-708, Republic of Korea
Published online on: May 20, 2016 https://doi.org/10.3892/or.2016.4825
Pages: 528-534

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma is one of the most aggressive skin cancer and highly resistant to most conventional treatment. In the present study, we aimed to investigate the anticancer effects and mechanisms of action of 7,8-dihydroxyflavone (7,8-DHF), a monophenolic flavone, in melanoma cells. At concentrations not exhibiting cytotoxicity, 7,8-DHF potently inhibited growth and clonogenic survival of alpha-melanocyte stimulating hormone (α-MSH)-stimulated B16F10 melanoma cells. Furthermore, it significantly blocked migration and invasion of the metastatic melanoma cells. We also observed that 7,8-DHF exhibits anti-melanogenic activity through inhibition of tyrosinase activity in α-MSH-stimulating condition. Notably, the suppressive activities of 7,8-DHF on melanoma progression were associated with the downregulation of microphthalmia-associated transcription factor (MITF) and its main downstream transcription targets, including hypoxia-inducible factor 1α (HIF1α) and c-MET, by a decrease in cyclic adenosine monophosphate (cAMP) level. In addition, combination treatment with 7,8-DHF and resveratrol, a known therapeutic agent against melanoma, had greater anticancer activities and MITF inhibition than treatment with each single agent in α-MSH-treated B16F10 cells. Collectively, these findings may contribute to the potential application of 7,8-DHF in the prevention and treatment of malignant melanoma.

View Figures

View References

1	Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
2	Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL and Chanmugam A: Cutaneous malignant melanoma. Mayo Clin Proc. 81:500–507. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kato M, Liu W, Akhand AA, Hossain K, Takeda K, Takahashi M and Nakashima I: Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in RFP-RET-transgenic mice. J Invest Dermatol. 115:1157–1158. 2000. View Article : Google Scholar : PubMed/NCBI
4	Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, et al: Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle. 4:1382–1384. 2005. View Article : Google Scholar : PubMed/NCBI
5	Hocker TL, Singh MK and Tsao H: Melanoma genetics and therapeutic approaches in the 21st century: Moving from the benchside to the bedside. J Invest Dermatol. 128:2575–2595. 2008. View Article : Google Scholar : PubMed/NCBI
6	Tsao H, Chin L, Garraway LA and Fisher DE: Melanoma: From mutations to medicine. Genes Dev. 26:1131–1155. 2012. View Article : Google Scholar : PubMed/NCBI
7	Levy C, Khaled M and Fisher DE: MITF: Master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 12:406–414. 2006. View Article : Google Scholar : PubMed/NCBI
8	Du J, Widlund HR, Horstmann MA, Ramaswamy S, Ross K, Huber WE, Nishimura EK, Golub TR and Fisher DE: Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell. 6:565–576. 2004. View Article : Google Scholar : PubMed/NCBI
9	Buscà R, Berra E, Gaggioli C, Khaled M, Bille K, Marchetti B, Thyss R, Fitsialos G, Larribère L, Bertolotto C, et al: Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol. 170:49–59. 2005. View Article : Google Scholar : PubMed/NCBI
10	McGill GG, Haq R, Nishimura EK and Fisher DE: c-Met expression is regulated by Mitf in the melanocyte lineage. J Biol Chem. 281:10365–10373. 2006. View Article : Google Scholar : PubMed/NCBI
11	Yasumoto K, Takeda K, Saito H, Watanabe K, Takahashi K and Shibahara S: Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J. 21:2703–2714. 2002. View Article : Google Scholar : PubMed/NCBI
12	Price ER, Horstmann MA, Wells AG, Weilbaecher KN, Takemoto CM, Landis MW and Fisher DE: alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. J Biol Chem. 273:33042–33047. 1998. View Article : Google Scholar : PubMed/NCBI
13	Wu M, Hemesath TJ, Takemoto CM, Horstmann MA, Wells AG, Price ER, Fisher DZ and Fisher DE: c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14:301–312. 2000.PubMed/NCBI
14	Bertolotto C, Abbe P, Hemesath TJ, Bille K, Fisher DE, Ortonne JP and Ballotti R: Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J Cell Biol. 142:827–835. 1998. View Article : Google Scholar : PubMed/NCBI
15	Beuret L, Flori E, Denoyelle C, Bille K, Busca R, Picardo M, Bertolotto C and Ballotti R: Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem. 282:14140–14147. 2007. View Article : Google Scholar : PubMed/NCBI
16	Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, et al: A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc Natl Acad Sci USA. 107:2687–2692. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chen J, Chua KW, Chua CC, Yu H, Pei A, Chua BH, Hamdy RC, Xu X and Liu CF: Antioxidant activity of 7,8-dihydroxyflavone provides neuroprotection against glutamate-induced toxicity. Neurosci Lett. 499:181–185. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhang R, Kang KA, Piao MJ, Ko DO, Wang ZH, Chang WY, You HJ, Lee IK, Kim BJ, Kang SS, et al: Preventive effect of 7,8-dihydroxyflavone against oxidative stress induced genotoxicity. Biol Pharm Bull. 32:166–171. 2009. View Article : Google Scholar : PubMed/NCBI
19	Han X, Zhu S, Wang B, Chen L, Li R, Yao W and Qu Z: Antioxidant action of 7,8-dihydroxyflavone protects PC12 cells against 6-hydroxydopamine-induced cytotoxicity. Neurochem Int. 64:18–23. 2014. View Article : Google Scholar
20	Lee RH, Shin JC, Kim KH, Choi YH, Chae JI and Shim JH: Apoptotic effects of 7,8-dihydroxyflavone in human oral squamous cancer cells through suppression of Sp1. Oncol Rep. 33:631–638. 2015.
21	Park HY, Kim GY, Hyun JW, Kim ND, Kim CG, Kim WJ, Yoo YH and Choi YH: 7,8-dihydroxyflavone induces g1 arrest of the cell cycle in U937 human monocytic leukemia cells via induction of the Cdk inhibitor p27 and downregulation of pRB phosphorylation. Oncol Rep. 28:353–357. 2012.PubMed/NCBI
22	Hunt G, Todd C, Cresswell JE and Thody AJ: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci. 107:205–211. 1994.PubMed/NCBI
23	Rusciano D, Lorenzoni P and Burger MM: Regulation of c-met expression in B16 murine melanoma cells by melanocyte stimulating hormone. J Cell Sci. 112:623–630. 1999.PubMed/NCBI
24	Poser I and Bosserhoff AK: Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol. 19:173–188. 2004.PubMed/NCBI
25	Riley PA: Melanogenesis and melanoma. Pigment Cell Res. 16:548–552. 2003. View Article : Google Scholar : PubMed/NCBI
26	Costin GE and Hearing VJ: Human skin pigmentation: Melanocytes modulate skin color in response to stress. FASEB J. 21:976–994. 2007. View Article : Google Scholar : PubMed/NCBI
27	Lee JH, Jang JY, Park C, Kim BW, Choi YH and Choi BT: Curcumin suppresses alpha-melanocyte stimulating hormone-stimulated melanogenesis in B16F10 cells. Int J Mol Med. 26:101–106. 2010.PubMed/NCBI
28	Jin SH, Lee YY and Kang HY: Methyl-beta-cyclodextrin, a specific cholesterol-binding agent, inhibits melanogenesis in human melanocytes through activation of ERK. Arch Dermatol Res. 300:451–454. 2008. View Article : Google Scholar : PubMed/NCBI
29	Gusman J, Malonne H and Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 22:1111–1117. 2001. View Article : Google Scholar : PubMed/NCBI
30	Chen YJ, Chen YY, Lin YF, Hu HY and Liao HF: Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid Based Complement Alternat Med. 2013:6321212013.PubMed/NCBI
31	Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, et al: Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
32	Osmond GW, Augustine CK, Zipfel PA, Padussis J and Tyler DS: Enhancing melanoma treatment with resveratrol. J Surg Res. 172:109–115. 2012. View Article : Google Scholar
33	Fulda S and Debatin KM: Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene. 23:6702–6711. 2004. View Article : Google Scholar : PubMed/NCBI